Sanofi teams up with India to make cheap ARVs in S.Africa

French pharmaceutical giant Sanofi has signed a partnership with India's Hetero to manufacture cheap anti-HIV drugs in South Africa, the company said on Friday.

"The agreement with Hetero will allow Sanofi to produce (anti-retrovirals) locally and contribute to the government's objective to secure 80 percent locally supplied ARVs," said Christopher Viehbacher, chief executive of Sanofi.

Sanofi, which has seven in six , has recently upgraded its factory north of Pretoria in order to meet the increased production.

Other factories are located in Algeria, Tunisia, Morocco, Egypt and Senegal.

"There is a continuous supply shortage for critical medicines for HIV/AIDS. Only 50 percent of patients are able to receive treatment and there is a real need for more locally manufactured and supplied affordable ARVs," Viehbacher said in a statement.

South Africa has one of the world's highest infection rate, with 5.6 million people with HIV, in a population of 50 million.

The South African government's ARV programme is the largest in the world, serving 1.3 million people.

"This agreement follows the government's priority to secure supply and create local jobs while providing quality medicines at affordable prices," he said.

According to the company, 80 million euros ($106.8 million) have been invested in Africa over the last five years and another 120 million euros will be invested over the next five years.

Related Stories

South Africa unveils plan to halve HIV infections

date Dec 01, 2011

President Jacob Zuma on Thursday unveiled a plan to halve the number of HIV infections over the next five years, cementing South Africa's turnaround from years of deadly denialism.

S. African to double HIV patient treatment

date Dec 14, 2010

(AP) -- South Africa's health minister says he has brought down the cost of HIV drugs by 53 percent, enabling the government to treat twice as many patients in the next two years.

S.Africa conducts trials for shorter TB treatment

date Mar 30, 2012

South African researchers said Friday they were conducting medical trials to shorten the duration of tuberculosis treatment to make it easier for patients to complete the full regimen.

Recommended for you

Study supports HPV vaccination guidelines

date 1 hour ago

(HealthDay)—New research finds that young women who get the HPV vaccine gain significant protection against infection in three parts of the body if they haven't already been exposed to the human papillomavirus.

Teva offers to buy Mylan in $40.1B cash-and-stock deal

date 5 hours ago

Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring ...

FDA warns of bogus botox

date Apr 20, 2015

(HealthDay)—Counterfeit Botox may have been distributed to doctors' offices and medical clinics across the United States, the U.S. Food and Drug Administration warns.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.